Beaten Down Biogen Stock Looks Attractive At Current Levels
The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. The company is executing a turnaround strategy that includes cost-cutting,...
Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript
Biogen Inc. (NASDAQ:BIIB ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael...
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Dise...
BRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO s...
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investo...
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Biogen reported its Q3 earnings yesterday, October 30. Revenue of $2.5bn was reported and non-GAAP EPS of $4.08. Growth was generally flat or declining for many key assets, with the performance of ...
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ET Company Participants Stephen Amato - Senior Director of IR Chris Viehbacher - President and CEO Priya Singhal...
Biogen's stock pops after earnings top estimates and company raises guidance
“We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline,” the company's CEO said.
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year profit guidance.
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the ...
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB) on...
Biogen Prepares for Q3 Earnings Call
Biotechnology firm Biogen Inc (NASDAQ:BIIB) is scheduled to report third-quarter results before the open on Wednesday, Oct. 30.
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
CAMBRIDGE, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 m...
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stock...
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
Biogen Inc.'s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial
Related Companies